CNS Pharmaceuticals (NASDAQ: CNSP), a preclinical stage biotechnology company, is looking to fill a gap in the treatment of Glioblastoma Multiforme (“GBM”), an aggressive form of cancer that occurs in the brain or spinal cord, with its lead product candidate Berubicin. “GBM is considered one of the most complex, deadly and treatment-resistant cancers. And although it is regarded as rare, between 12,000 and 15,000 Americans are diagnosed with the condition every year. Even more devastatingly, the National Brain Tumor Society (‘NBTS’) estimates that over 10,000 individuals with GBM succumb to the disease annually. GBM has a five-year survival rate of only 6.8%, and the average length of survival for patients is estimated to be eight months,” explains a recent article. “Against the backdrop of statistics that show the aggressiveness of GBM, CNS is leading the charge to find a potential treatment option for the disease. ‘In the results of the first Berubicin clinical trial, 44% of the patients showed a clinical response, with one Durable Complete Response (a demonstrated lack of detectable cancer cells,’ CNS’s website reads. ‘Berubicin has shown evidence of improved survival in a patient population that currently has a dismal median survival rate of only 14.6 months from its diagnosis.’ Currently, the company is focusing on an ongoing, potentially pivotal global study that commenced in March last year.”
To view the full article, visit https://ibn.fm/DAcsk
About CNS Pharmaceuticals Inc.
CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The company’s lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma (“GBM”), an aggressive and incurable form of brain cancer. Additionally, the company is advancing the development of its WP1244 drug technology portfolio, which utilizes anthracycline and distamycin-based scaffolds to create small molecule agents and is believed to be 500x more potent than daunorubicin in inhibiting tumor cell proliferation. Preclinical studies of WP1244 demonstrated high uptake in the brain with antitumor activity. CNS Pharmaceuticals is evaluating the use of WP1244 in the treatment of brain cancers, pancreatic, ovarian, and lymphomas. For more information, visit the company’s website at www.CNSPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.qualitystocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php